1887
  1. Home
  2. Eurosurveillance
  3. Volume 24, Issue 8, 21/Feb/2019
  4. Article
Research Open Access
Like 0
Download

Abstract

Background: Opportunistic human papillomavirus (HPV) vaccination for men who have sex with men (MSM) was piloted in sexual health clinics (SHC) in England between 2016 and 2018.

Aim: to evaluate the pilot’s first year (April 2016–March 2017) in terms of feasibility, acceptability, uptake, impact and equity and interpret the outcome in the context of wide HPV vaccination policy.

Methods: Attendance and uptake data from routine SHC surveillance datasets and a cross-sectional survey administered to individuals receiving the vaccine were analysed.

Results: Among 18,875 eligible MSM, 8,580 (45.5%) were recorded as having received one HPV vaccine dose, decreasing slightly with increasing age, and uptake was higher in rural than urban areas. Survey results suggested that of those receiving the first dose of HPV vaccine, 8% were new attendees and that among those, less than 11% attended just to receive the vaccine. Of those having their first HPV vaccination, 95% indicated they would like to receive the next vaccine doses at the same clinic and 85% of patients reported accessing other services when visiting SHC for the first dose of vaccine.

Conclusion: An opportunistic HPV vaccination programme for MSM can be delivered in an acceptable and, as far as can be evaluated, equitable manner, without major disruption to SHC and HIV clinics.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.8.1800055
2019-02-21
2024-04-19
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.8.1800055
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/8/eurosurv-24-8-6.html?itemId=/content/10.2807/1560-7917.ES.2019.24.8.1800055&mimeType=html&fmt=ahah

References

  1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.  https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F  PMID: 10451482 
  2. Hawkins MG, Winder DM, Ball SL, Vaughan K, Sonnex C, Stanley MA, et al. Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J. 2013;10(1):137.  https://doi.org/10.1186/1743-422X-10-137  PMID: 23634957 
  3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S11-25.  https://doi.org/10.1016/j.vaccine.2006.05.111  PMID: 16949997 
  4. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 2008;5(1):24-31.  https://doi.org/10.1038/ncponc0984  PMID: 18097454 
  5. Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer. 2007;96(9):1320-3.  https://doi.org/10.1038/sj.bjc.6603695  PMID: 17375045 
  6. Mesher D, Cuschieri K, Hibbitts S, Jamison J, Sargent A, Pollock KG, et al. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. J Clin Pathol. 2015;68(2):135-40.  https://doi.org/10.1136/jclinpath-2014-202681  PMID: 25410654 
  7. Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80.  https://doi.org/10.1016/S1473-3099(14)71073-4  PMID: 25744474 
  8. Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, et al. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2017;64(5):580-88.  https://doi.org/10.1093/cid/ciw845  PMID: 28011615 
  9. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346(apr18 1):f2032.  https://doi.org/10.1136/bmj.f2032  PMID: 23599298 
  10. Public Health England (PHE). Sexually transmitted infections (STIs): annual data tables. London: PHE; 2010. Available from: https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables
  11. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270-80.  https://doi.org/10.1002/cncr.20365  PMID: 15241823 
  12. Department of Health and Social Care. HPV vaccine to be given to boys in England. London: Department of Health and Social Care; July 2018. Available from: https://www.gov.uk/government/news/hpv-vaccine-to-be-given-to-boys-in-england
  13. National Health Service (NHS). JCVI Statement on HPV vaccination for MSM. London: NHS; 2015. Available from: https://www.gov.uk/government/publications/jcvi-statement-on-hpv-vaccination-of-men-who-have-sex-with-men
  14. Public Health England (PHE). HPV vaccination for men who have sex with men: year 1 pilot. London: PHE; February 2018. Available from: https://www.gov.uk/government/publications/hpv-vaccination-for-men-who-have-sex-with-men-year-1-pilot
  15. Public Health England (PHE). Genitourinary Medicine Clinic Activity Dataset. London: PHE; December 2013. Available from: https://www.gov.uk/guidance/gumcad-sti-surveillance-system
  16. Public Health England (PHE). The HIV and AIDS Reporting System (HARS). HIV surveillance systems. London: PHE; 2016. Available from: https://www.gov.uk/guidance/hiv-surveillance-systems#the-hiv-and-aids-reporting-system-hars
  17. Public Health England (PHE). Producing estimates of the size of the LGB population of England. London: PHE; January 2017. Available from: https://www.gov.uk/government/publications/producing-estimates-of-the-size-of-the-lgb-population-of-england
  18. Office for National Statistics (ONS). Annual Mid-year Population Estimates: 2014. London: ONS; 2014. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/2015-06-25
  19. Bayley J, Mesher D, Nadarzynski T, Hughes G, Soldan K. Attendance of MSM at Genitourinary Medicine services in England: implications for selective HPV vaccination programme (a short communication). Sex Transm Infect. 2018;94(7):542-544.
  20. National Health Service (NHS). Data dictionary: lower super output area. London: NHS. [Accessed 13 Feb 2019 ]. Available from: https://www.datadictionary.nhs.uk/data_dictionary/nhs_business_definitions/l/lower_layer_super_output_area_de.asp?shownav=1
  21. Public Health England (PHE). HPV vaccination for men who have sex with men (MSM) programme. London: PHE; March 2018. Available from: https://www.gov.uk/government/collections/hpv-vaccination-for-men-who-have-sex-with-men-msm-programme
  22. Public Health England (PHE). Immunisation against infectious disease: Chapter 18a: HPV. London: PHE; June 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/317821/Green_Book_Chapter_18a.pdf
  23. European Centre for Disease Prevention and Control (ECDC). Vaccine schedules in all countries of the European Union. Stockholm: ECDC. [Accessed 13 Feb 2019 ]. Available from: https://vaccine-schedule.ecdc.europa.eu/
  24. Prue G, Baker P, Graham D, Nutting C, Greenhouse P, Lawler M. It is time for universal HPV vaccination. Lancet. 2018;392(10151):913-4.  https://doi.org/10.1016/S0140-6736(18)31821-X  PMID: 30238882 
  25. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733-44.  https://doi.org/10.2165/00019053-200826090-00004  PMID: 18767894 
Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Michael+Edelstein&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Edelstein Michael</a>, <a href="/search?value1=Nalini+Iyanger&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Iyanger Nalini</a>, <a href="/search?value1=Nicola+Hennessy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hennessy Nicola</a>, <a href="/search?value1=David+Mesher&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mesher David</a>, <a href="/search?value1=Marta+Checchi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Checchi Marta</a>, <a href="/search?value1=Kate+Soldan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Soldan Kate</a>, <a href="/search?value1=Mark+McCall&option1=author&noRedirect=true" class="nonDisambigAuthorLink">McCall Mark</a>, <a href="/search?value1=Julie+Nugent&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nugent Julie</a>, <a href="/search?value1=Jonathan+Crofts&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Crofts Jonathan</a>, <a href="/search?value1=Janice+Lo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lo Janice</a>, <a href="/search?value1=Richard+Gilson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gilson Richard</a>, <a href="/search?value1=Karen+Powell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Powell Karen</a>, <a href="/search?value1=Mary+Ramsay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ramsay Mary</a>, <a href="/search?value1=Joanne+Yarwood&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Yarwood Joanne</a></span>. Implementation and evaluation of the human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM), England, April 2016 to March 2017. <a href="/content/ecdc">Euro Surveill.</a> 2019;24(8):pii=1800055. <a href="https://doi.org/10.2807/1560-7917.ES.2019.24.8.1800055" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2019.24.8.1800055</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 02 Feb 2018;&nbsp;&nbsp; <span class="generated">Accepted</span>: 21 Dec 2018 </span> </p>
/content/10.2807/1560-7917.ES.2019.24.8.1800055
/content/10.2807/1560-7917.ES.2019.24.8.1800055
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error